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Introduction 
Founded in 1985, Chronimed is a small-cap health care company that started with a fairly unique 
business plan - being a one-stop shop for those with diabetes. The idea at the time was that 
through specialization in diabetes, the company could improve outcomes for its customers, 
enhance their quality of life, and better manage health care costs (these are the three points of the 
company's mission statement). As time passed, the company expanded its focus to additional 
chronic diseases, including organ transplant and HIV / AIDS patients, among others. Chronic 
diseases are extremely complex and extremely costly, as 45% of Americans suffer from chronic 
conditions that account for about 75% of U.S. health care spending. Specifically, Chronimed 
focuses on diseases that have average annual pharmaceutical costs of over $20,000 per patient. 
In 1992, Chronimed went public and experienced rapid growth, with revenues almost tripling 
and profits almost quadrupling since fiscal 1994. Subsequently, the company was named one of 
Fortune's "100 Fastest-Growing Companies" in 1997 and 1998 (based on the earnings per share 
growth rate for the three previous years). The company was also named as one of Financial 
World's "100 Hottest Small Companies" in 1998. Refer to Exhibit 1 for condensed Chronimed 
financial statements. 
Business Strategy Analysis 
Chronimed's primary businesses are (1) a mail-order pharmacy for organ transplant patients and 
patients who use biotech injectibles, (2) a chain of retail pharmacies for HIV/AIDS patients, and 
(3) a manufacturer and distributor of diabetes test equipment. Further, Chronimed also 
distributes other companies' diabetes test equipment through its mail-order pharmacy, catalog, 
and sales force for institutional customers. 
Chronimed's vision of providing quality health care services and products to chronically ill 
patients at competitive prices has remained relatively unchanged over the past 15 years; the only 
change has been an increased emphasis on cost control. The company's specialization in 
complex, chronic diseases allows it to be more familiar with its customers and their health risks, 
and, therefore, provide valuable consultation to patients and their doctors. Moreover, these 
customers use a great deal of high-cost pharmaceuticals and medical products over their entire 
lives, which provides the company with a stable, annuity-like revenue base from which to 
operate and grow. Chronimed's strategy also enhances patient retention and differentiates the 
company from its competitors. 
The company emphasizes that its service provides a benefit to insurance companies and other 
payers, as it leads to lower long-term health care costs through improved drug compliance and 
overall better disease management. Unfortunately, the company has no proof of this advantage, 
as such a study would be prohibitively expensive and time-consuming, according to the 
company. Consequently, the company has not pursued this avenue. Accordingly, Chronimed 
has been unable to charge more for its services, as it must compete on price. Consequently, the 
company is under significant price pressure from bigger, less specialized competitors who have 
greater scale economies. In conclusion, while the company has many advantages, it will be 
difficult for the company to leverage these advantages into profits until it can either prove the 
value of these benefits or grow large enough that it can compete on scale. 
Accounting Analysis 
Chronimed's accounting policies seem straightforward. For example, accounts receivables 
(A/R) for a company like Chronimed are somewhat at the whim of insurance agencies and other 
payers with respect to the amount and timing of payments. Measures of A/R management 
include an allowance for doubtful accounts, which has been holding steady at 5.2% over the past 
two years, and A/R as a percentage of sales, which has been declining: 21.9% in 1996, 17.4% in 
1997, and 16.5% in 1998. This decline can be attributed to its "clean-up" of its A/R in 1997, 
which subsequently lowered both the allowance for doubtful accounts and the write-offs in 1998. 
Because Chronimed has been actively growing through acquisition, goodwill is a significant part 
of its balance sheet, representing $16.3 million in 1998 (or 22% of total assets). Chronimed 
amortizes goodwill on a straight-line basis over two to 20 years, although its most recent 
acquisitions have been amortized over seven or 12 years. However, while these numbers seem 
reasonable, Chronimed provides no justification as to how they are chosen for any particular 
purchase. Thus, it is difficult to tell if the company uses goodwill as a significant earnings 
management lever. 
Finally, Chronimed appears to have few "red flags" associated with its accounting methods and 
financial reporting. Based on our analysis, the following items represent potential "red flags": 
• Chronimed's cash from operations (CFO) has been decreasing over the last three years and 
dropped significantly below net income for the first time in 1998. This drop is due to an 
increase in working capital assets, while paying down accounts payable. 
• In 1997, Chronimed wrote-off $1.4 million for a loan to Health Craft International, Inc. (HCI) 
as a one-time charge. This money was loaned to HCI for the research and development of 
new diabetes monitoring technology. Since the technology was never proven viable, the loan 
was determined to be unrecoverable. Chronimed waited, however, to write-off this note until 
it had an unusual gain (a sale of distribution rights) to offset the loss. Since Chronimed does 
not have other loans of this nature, this issue may be minor, but the timing of the write-off 
may be indicative of earnings management. 
• Chronimed expects no material effect due to the Year 2000 system problem, but it is very 
likely that they will be impacted by their payers, since the health care industry generally uses 
old, mainframe-based systems. While it is unclear how this issue will impact Chronimed, a 
short-term increase in its accounts receivable can be expected. 
Financial Analysis 
We analyzed and benchmarked two companies against Chronimed's financial performance. The 
first company, CVS Corporation, the nation's second largest retail drug store chain, was selected 
because Chronimed also operates a small chain of retail pharmacy stores. The second company 
identified was Bergen Brunswig, a manufacturer of medical-surgical supplies to hospitals and 
managed care facilities. Chronimed similarly manufacturers medical supplies, such as blood 
glucose monitors, to managed care organizations and to patients directly. 
Using the DuPont model to calculate the return on equity (ROE) for each company, CVS has the 
highest return (CVS 15.9%, Chronimed 13.4%, Bergen Brunswig .5%). Refer to Exhibit 2 for 
the financial ratios of all three companies. Profit margins for all three companies are relatively 
low, as distributors get squeezed on price from the drug manufacturers and the payers (i.e., 
insurance companies). Distribution, in general, is characterized by small profit margins, 
especially in this industry. Looking forward, Chronimed has the opportunity to increase its profit 
margins by achieving scale efficiencies in manufacturing operations, continuing to build brand 
equity in its pharmacy business, and pushing its Diagnostic business unit's proprietary high-
margin products. 
The asset turnover ratio for all three companies increased between 1997 and 1998. For CVS and 
Chronimed, economies of scale in the number of retail stores and distribution centers have 
contributed to higher turnovers. Bergen Brunswig has the highest asset turnover and leverage 
since its primary business is medical supply manufacturing, which employs relatively few, but 
highly productivity machines. Chronimed can expect to increase its asset turnover as it grows 
and gains economies of scale from its distribution facilities. 
Chronimed operates with very little leverage (1.22), as it virtually has no debt. In comparison, 
Bergen Brunswig's leverage ratio is 4.3, while CVS' is 2.7. Since its incorporation, Chronimed 
has used essentially no debt financing, since it has traditionally kept large reserves of cash on 
hand. A cash flow analysis shows that the company did not begin to spend the proceeds of its 
1994 seasoned equity offering until 1996. As of 1997, the company still had $15.3 million in 
cash and investments - although this balance dropped to $7.5 million in 1998. This decrease was 
primarily due to several acquisitions and a stock repurchase program. Further, while leverage 
maybe the easiest aspect of the DuPont model to alter, Chronimed may wish to maintain its 
current level of leverage. However, if the company continues to pursue acquisitions at its current 
pace, it may become necessary for it to take on more debt and thus increase its leverage. 
With regard to sustaining its ROE in the long-term, the company should be able to at least 
maintain its profit margin, while increasing asset turnover and leverage. However, this might not 
be the case in the short-term as Chronimed is under price pressures in its Specialty Pharmacy 
Services business. Additionally, Chronimed's ROE has yet to match or exceed its required cost 
of equity (approximately 14.9%) in any of the years studied. Thus, even if the company can 
maintain its current ROE, it will continue to destroy shareholder value unless it can improve 
upon its ROE. This goal, however, does seem attainable. 
Prospective Analysis 
Utilizing the discounted abnormal earnings valuation model and our assumptions, we arrived at a 
value of about $11.49 per share of Chronimed, in contrast to the April 2, 1999 market close of 
$6,125. Refer to Exhibits 3 and 4 for the full details of the model. 
In using the abnormal earnings model, we undertook several steps. First, we determined the 
appropriate discount rate using the CAPM formula, with 5.25% as the risk-free rate, 7.2% as the 
market premium, and 1.34 as Chronimed's beta. Making these assumptions results in a required 
return on equity of 14.9% for the company. 
Next, we estimated Chronimed's financial statements through 2005, with this last year serving as 
the first year of a non-growing perpetuity, which we used to calculate the terminal value. Given 
Chronimed's recent press release regarding lower than expected performance, we adjusted its 
operating margin down for 1999 (below last year's performance). We matched our 1999 
earnings ($0.63) to the prevailing market forecast. 
Given the company's historical rate of revenue growth of approximately 30% per year and its 
increasing asset turnover ratio (a projected ratio of 2.39 for 1999), we sought to keep sales 
growth high, but in balance with asset turnover. With that in mind, we projected 20% revenue 
growth for 2000, with following years' sales tied to the 2000 asset turnover number (kept 
constant at 2.58). We also believe that gross margins will return to historical levels of 30%, as 
the company grows its higher margin Diagnostic Products and Disease Management divisions. 
We have phased this increase in over four years, increasing gross margin 1% every two years. 
For SG&A, we believe that the company will improve its spending efficiencies (per recent 
company announcements), and have also phased in a 1% spending cut every two years, until 
SG&A falls to 19% of revenue. 
In the base case, we have assumed that the leverage ratio will increase slightly - due to the 
company maintaining its growth rate, but depleting its available cash (as mentioned above). As a 
result, Chronimed can either finance this growth through expansion of its A/P (which has been 
shrinking) or through the issuance of debt (of which it currently has none). 
Given the above assumptions, the indicated value per share of Chronimed is $11.49. This likely 
differs from the current market valuation due to the recent announcements made by Chronimed 
about short-term difficulties. A similar situation occurred in 1995, and the market responded in 
the similar fashion, before pushing the stock to all-time highs in 1996. In short, the market is 
very likely over-reacting to recent announcements by Chronimed, but will return to early-1999 
levels of between $10 and $14. We feel that our estimates are reasonable given the company's 
historical performance and the current business environment and outlook. Further, if the 
company decides to make any significant change in its capital structure, it would easily support a 
price above the current market price. For sensitivities, we looked at the following: 
• Keeping 1999 financial results as a perpetuity (for a result of $4.29 a share) 
• Keeping 1999 financial results as a perpetuity, but undertaking a re-capitalization in 2000 to 
get a 2.0 leverage ratio ($7.35) 
• Taking the base case assumptions, but a constant leverage ratio ($9.18) 
• Taking the base case, but with the leveraged re-capitalization in 2000 ($15.60) 
Clearly, the company can easily change its leverage ratio and increase its ROE and valuation. 
Thus, it makes sense to build this increased leverage into the forecast with the assumption that 
management will increase leverage in the future to increase shareholder return on equity. How 
much they will increase leverage is really the question. Clearly, management needs to ensure 
that any increase in leverage can be done without significantly decreasing its flexibility. 
In summary, we believe that our P&L forecasts are reasonable and within historical performance, 
and our leverage forecasts are reasonable to conservative. Therefore, we recommend a "buy" for 
Chronimed since our base-case forecasts indicate modest performance improvements will yield a 
price nearly 90% above the current market valuation. 
Exhibit 1: Chronimed Financial Statements 
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Other Current Assets 
Total Current Assets 
Net Fixed Assets 




Other Current Liabilities 
Total Current Liabilities 
Long-Term Debt 
Other Non-Current Liabilities 
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Common Stock Equity 
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Cash Flow Statement 
Net Cash from Operations 
Net Cash from Investing 
Net Cash from Financing 
Net Change in Cash 























Exhibit 2: Comparative Ratio Analysis 
DuPont Model 
Profit Margin 
Asset Turnover Ratio 
Leverage Ratio 
Return on Equity 
x (1 - Dividend Payout Ratio) 
Sustainable Growth Rate 
Profit Margin 
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Exhibit 3: Chronimed Forecasted Financials 
Exhibit 4: Chronimed Valuation 

